{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieebvhhxmengkssezjpwf67cqyuwkvmoqaugwftzc5eyb6pyw3iqm",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mixjse27lvl2"
  },
  "path": "/2026/04/08/everest-medicines-signs-share-purchase-agreement-with-hasten-biopharmaceuticals-asia-limited/",
  "publishedAt": "2026-04-08T02:21:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments Delivers near-term revenue and profitability with 2025 normalized revenue of US$82,232,000 (approximately RMB566,299,000) with an EBITDA of US$27,273,000 (approximately RMB187,818,000). Strong synergies with Everest’s existing portfolio and enhances […]",
  "title": "Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited"
}